Deferoxamine in Aneurysmal Subarachnoid Hemorrhage Trial
Status:
Unknown status
Trial end date:
2018-06-01
Target enrollment:
Participant gender:
Summary
Aneurysmal subarachnoid hemorrhage (SAH) is a form of stroke in which secondary neurological
deterioration is an important cause of mortality and morbidity. These secondary changes, so
called delayed cerebral ischemia (DCI), are caused by lysis of erythrocytes which can react
to form iron, an toxic substance to the brain. Iron chelators remove the excess of iron and
are standard care in iron-overloaded patients. Deferoxamine (DFO) an chelator has not been
evaluated in SAH patients. This study evaluates the safety of deferoxamine in SAH patients